Arsenic Used to Fight Warrior Cancer Cells
Posted on: Tuesday, 13 May 2008, 00:00 CDT
Medical researchers in Boston say arsenic can be used in conjunction with chemotherapy to treat chronic myeloid leukemia.
The research team led by Dr. Pier Paolo Pandolfi , a Harvard Medical School professor and head of the Cancer Genetics Program in Beth Israel Deaconess Medical Center, found that arsenic-based therapies successfully target leukemia initiating cells, or LICs, that are impervious to conventional chemotherapy.
The findings, published online in the journal Nature, suggest the tumor suppressor protein PML can be degraded with an arsenic-based agent used in traditional Chinese medicine. The hospital said the therapy has proven safe and non-toxic in clinical trials.
Ninety percent of existing cancer treatments are antiproliferative agents -- they target the pool of proliferative cells, leaving behind the dormant LICs, Panolfi said in a statement. But in determining that PML serves to guard the LICs that have been left behind, we also discovered that if we knock out PML (through pharmacologic means), the LICs will lose their braking abilities and run out of gas, thereby committing the fatal error of proliferation -- and exposing themselves to the deadly effects of cancer therapies.
Source: United Press International
Related Articles
- Tool Added to Center's Cancer-Fighting Arsenal
- Men's Health Policy Center Hosts Petition to Protest Government Barrier to Prostate Cancer Medications
- Hospira Launches Generic Cancer Medication
- Epigenomics AG Forms Medical Advisory Board For Colorectal Cancer Screening
- Cheap Cancer Medication
- Hospitals Work to Reduce Medical Injuries
- Misonix Spotlights HIFU Medical Devices for Prostate and Kidney Cancer Treatment at European Association of Urology Conference 2007
- Therapies Targeted for Kidney Cancer
- Tarceva OK'D for Cancer of Pancreas
- Prostate Cancer Therapy May Affect Mental Function
User Comments (0)
RSS Feeds